{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134796","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.313382+00:00","generated_at":"2026-06-02T06:47:47.133141+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Disc Medicine Q1 net loss $26.9M; bitopertin AURORA trial misses primary endpoint, but shows secondary benefits","bullets":["Cash and cash equivalents $342.6M at March 31, 2024; provides runway well into 2026.","Net loss $26.9M in Q1 2024 vs. $22.8M in Q1 2023; R&D expense rose to $23.7M from $20.2M.","Bitopertin AURORA phase 2 in EPP: significant PPIX reduction; missed primary endpoint (light tolerance) due to placebo benefit; 60mg dose showed significant reduction in phototoxic pain reactions.","Received FDA Rare Pediatric Disease Designation for bitopertin in EPP in May 2024.","On track to present additional AURORA/BEACON data, initial DISC-3405 SAD data, and updated DISC-0974 MF data in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134796","json":"https://secwatch.observer/filing/0001193125-24-134796.json","markdown":"https://secwatch.observer/filing/0001193125-24-134796.md","text":"https://secwatch.observer/filing/0001193125-24-134796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524134796/0001193125-24-134796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524134796/d827802d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:47:47.133141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54d1a1d4e9bf0843b2645a6395df90e1e3c360c6","claim":"Disc Medicine, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $26.9 million.","evidence_excerpt":"Disc Medicine, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524134796/0001193125-24-134796-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $26.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}